Axonal transport of AAV9 in nonhuman primate brain

Gene Therapy

Volumn 23, Issue 6, 2016, Pages 520-526

  Green, F ^a   Samaranch, L ^a   Zhang, H S ^b   Manning Bog, A ^b   Meyer, K ^b   Forsayeth, J ^a   Bankiewicz, K S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANGAMO BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; NEURON SPECIFIC NUCLEAR PROTEIN;

ADENO ASSOCIATED VIRUS 9; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; ASTROCYTE; BASAL GANGLION; BRAIN CELL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG MEGADOSE; GENE EXPRESSION; GLOBUS PALLIDUS; HUNTINGTON CHOREA; IMMUNOTOXICITY; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDIAL FOREBRAIN BUNDLE; MICROGLIA; NERVE FIBER TRANSPORT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIMATE; PRIORITY JOURNAL; PUTAMEN; RHESUS MONKEY; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; THALAMUS; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VOLUME OF DISTRIBUTION; ANIMAL; BIOSYNTHESIS; BRAIN; CORPUS STRIATUM; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; NERVE CELL; PHYSIOLOGY; PROCEDURES; SUBSTANTIA NIGRA; VIROLOGY;

ANIMALS; ANTIGEN-PRESENTING CELLS; ASTROCYTES; AXONAL TRANSPORT; BRAIN; CORPUS STRIATUM; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; MACACA MULATTA; MICROGLIA; NEURONS; PILOT PROJECTS; PUTAMEN; SUBSTANTIA NIGRA; TRANSDUCTION, GENETIC;

EID: 84961390363     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2016.24     Document Type: Article

References (33)

1. Fiandaca MS, Varenika V, Eberling J, McKnight T, Bringas J, Pivirotto P et al. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage 2009; 47 (Suppl 2): T27-T35.
2. Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, Larson PS et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther 2011; 19: 1048-1057.
3. Ciesielska A, Mittermeyer G, Hadaczek P, Kells AP, Forsayeth J, Bankiewicz KS. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther 2011; 19: 922-927.
4. Kells AP, Forsayeth J, Bankiewicz KS. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol Dis 2012; 48: 228-235.
5. Salegio EA, Samaranch L, Kells AP, Mittermeyer G, San Sebastian W, Zhou S et al. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther 2012; 20: 348-352.
6. San Sebastian W, Samaranch L, Heller G, Kells AP, Bringas J, Pivirotto P et al. Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain. Gene Ther 2013; 20: 1178-1183.
7. Ciesielska A, Hadaczek P, Mittermeyer G, Zhou S, Wright JF, Bankiewicz KS et al. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cellmediated immune responses. Mol Ther 2013; 21: 158-166.
8. Samaranch L, San Sebastian W, Kells AP, Salegio EA, Heller G, Bringas JR et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigenpresenting cell transduction. Mol Ther 2014; 22: 329-337.
9. Richardson RM, Kells AP, Martin AJ, Larson PS, Starr PA, Piferi PG et al. Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg 2011; 89: 141-151.
10. Cornet A, Bettelli E, Oukka M, Cambouris C, Avellana-Adalid V, Kosmatopoulos K et al. Role of astrocytes in antigen presentation and naive T-cell activation. J Neuroimmunol 2000; 106: 69-77.
11. Nelson PT, Soma LA, Lavi E. Microglia in diseases of the central nervous system. Ann Med 2002; 34: 491-500.
12. Kells AP, Hadaczek P, Yin D, Bringas J, Varenika V, Forsayeth J et al. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci USA 2009; 106: 2407-2411.
13. San Sebastian W, Kells AP, Bringas J, Samaranch L, Hadaczek P, Ciesielska A et al. Safety and tolerability of mri-guided infusion of aav2-haadc into the mid-brain of non-human primate. Mol Ther Methods Clin Dev 2014; 3: 14049.
14. Hadaczek P, Yamashita Y, Mirek H, Tamas L, Bohn MC, Noble C et al. The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 2006; 14: 69-78.
15. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
16. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 2011; 286: 13532-13540.
17. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011; 19: 1058-1069.
18. Hinderer C, Bell P, Vite CH, Louboutin J-P, Grant R, Bote E et al. Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol Ther Methods Clin Dev 2014; 1: 14051.
19. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27: 59-65.
20. Forsayeth J, Bankiewicz KS. Transduction of antigen-presenting cells in the brain by AAV9 warrants caution in preclinical studies. Mol Ther 2015; 23: 612.
21. Costantini LC, Jacoby DR, Wang S, Fraefel C, Breakefield XO, Isacson O. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adenoassociated virus amplicon vectors. Hum Gene Ther 1999; 10: 2481-2494.
22. Diefenbach RJ, Miranda-Saksena M, Douglas MW, Cunningham AL. Transport and egress of herpes simplex virus in neurons. Rev Med Virol 2008; 18: 35-51.
23. Lilley CE, Groutsi F, Han Z, Palmer JA, Anderson PN, Latchman DS et al. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J Virol 2001; 75: 4343-4356.
24. McGraw HM, Friedman HM. Herpes simplex virus type 1 glycoprotein E mediates retrograde spread from epithelial cells to neurites. J Virol 2009; 83: 4791-4799.
25. Gillet JP, Derer P, Tsiang H. Axonal transport of rabies virus in the central nervous system of the rat. J Neuropathol Exp Neurol 1986; 45: 619-634.
26. Kelly RM, Strick PL. Rabies as a transneuronal tracer of circuits in the central nervous system. J Neurosci Methods 2000; 103: 63-71.
27. Klingen Y, Conzelmann KK, Finke S. Double-labeled rabies virus: live tracking of enveloped virus transport. J Virol 2008; 82: 237-245.
28. Larsen DD, Wickersham IR, Callaway EM. Retrograde tracing with recombinant rabies virus reveals correlations between projection targets and dendritic architecture in layer 5 of mouse barrel cortex. Front Neural Circuits 2007; 1: 5.
29. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301: 839-842.
30. Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G et al. Pathophysiology of chorea and bradykinesia in Huntington's disease. Mov Disord 1999; 14: 398-403.
31. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998; 5: 938-945.
32. Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 2005; 103: 923-929.
33. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 2008; 5: 123-127.